Acknowledgement: Patient Worthy is proud to share this article from our friends at the Fatty Liver Foundation. As a patient, what I really want to understand is how damaged is…
The U.S. Food and Drug Administration (FDA) reported the approval of semaglutide injections for metabolic dysfunction-associated steatohepatitis (MASH), marking a major milestone in the fight against this increasingly common and…
ACKNOWLEDGEMENT – Patient Worthy is honored to partner with The Fatty Liver Foundation to provide you with this article. The Fatty Liver Foundation aims to improve the diagnosis, treatment & support…
Madrigal Pharmaceuticals is making significant strides in its mission to address metabolic dysfunction-associated steatohepatitis (MASH), as the company’s lead drug, REZDIFFRA, edges closer to regulatory approval in the European Union.…
Madrigal Pharmaceuticals has recently captured significant attention in the race to treat metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). As the landscape of liver disease therapeutics evolves,…
The results released from the Phase III ESSENCE clinical trial, and recently published by Medical Xpress and in the NEJM, found that the drug semaglutide is effective in the treatment…
Madrigal today released their first report of results following FDA approval of Rezdiffra for the treatment of NASH in April. Their results are on track according to company forecasts but…
Written by Bill Clark Part 2 - Our Journey from Liver Failure to Transplant Continued from Part 1 “A new liver.” That was Becky’s answer pretty much every morning from…
Written by Bill Clark Part 1 - Our Journey from Fatty Liver to Liver Failure Becky's fight is our fight. That became my "rallying cry” early on when my wife…
According to a press release from the US Food and Drug Administration (FDA), the agency has approved the medication resmetirom (marketed as Rezdiffra) as the first-ever treatment intended to treat…
Over the past few years, Akero Therapeutics has experienced high highs and low lows in its efforts to advance efruxifermin, an investigational drug for people living with metabolic dysfunction-associated steatohepatitis…
According to a story from Healio, encouraging results from a phase 2 trial could herald a new standard of treatment for metabolic dysfunction-associated steatohepatitis (MASH). The investigational therapy is called…
Metabolic dysfunction-associated steatohepatitis (MASH) unfortunately has no treatments to reverse the disease or its damage. MASH can be managed through weight loss, regular exercise, and blood sugar management. But identifying…
According to a story from Healio, Rohit Kohli, MBBS, MS, division chief of gastroenterology, hepatology and nutrition at Children’s Hospital Los Angeles, spoke at the World Congress on Insulin Resistance, Diabetes…
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
The U.S. Food and Drug Administration offers various designations to drugs and drug developers to both incentivize medical advancements in the rare disease space and get treatments in the…
An estimated 25% of people in the United States have a condition called nonalcoholic fatty liver disease (NAFLD), a condition characterized by excess fat in the liver. Estimates vary but…
According to a story from Healio, in a phase 3 clinical trial, treatment with the drug resmetirom was able to achieve the desired endpoints at 52 weeks in people living…
In the last decade, NAFLD in pregnancy has nearly tripled in concert with the worldwide increase in diabetes. Mayo Clinic reports that NAFLD in general affects one-fourth of the…
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
Right now, there are limited pharmacological therapies available for people with nonalcoholic steatohepatitis (NASH). Rather, treatment options focus on healthy diet and exercise, weight loss, alcohol avoidance, lower cholesterol, and…
By definition, NASH or nonalcoholic steatohepatitis is a form of fatty liver disease. NASH may be a result of a metabolic disorder such as diabetes or obesity that develops…
In late June 2022, Patient Worthy discussed how doctors and scientists were concerned about rising rates of nonalcoholic fatty liver disease (NAFLD) in Filipinos. But according to new research, the…
Altogether, an estimated 15-30% of people around the globe have nonalcoholic fatty liver disease (NAFLD), a condition in those who drink very little or not at all which mimics liver…
LPCN 1144 for nonalcoholic steatohepatitis (NASH) has already demonstrated positive results in the LiFT trial, and it is now showing more exciting results in its open-label extension (OLE) trial. Want…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
